Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy

Head & Neck ◽  
2013 ◽  
Vol 36 (8) ◽  
pp. 1120-1125 ◽  
Author(s):  
Donald M. Cannon ◽  
Heather M. Geye ◽  
Gregory K. Hartig ◽  
Anne M. Traynor ◽  
Tien Hoang ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Radiation Treatment ◽  
Treatment Time ◽  
Concurrent Chemotherapy ◽  
Local Failure ◽  
Failure Risk ◽  
Radiation Treatment Time

scholarly journals The Impact of Radiation Treatment Time on Survival in Patients With Head and Neck Cancer

2016 ◽  
Vol 96 (5) ◽  
pp. 967-975 ◽  
Author(s):  
Talha Shaikh ◽  
Elizabeth A. Handorf ◽  
Colin T. Murphy ◽  
Ranee Mehra ◽  
John A. Ridge ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Radiation Treatment ◽  
Treatment Time ◽  
Radiation Treatment Time ◽  
The Impact

scholarly journals Development of a Web-Based Supportive Care Program for Patients With Head and Neck Cancer

2020 ◽  
Vol 10 ◽  
Author(s):  
Carolyn Y. Fang ◽  
Thomas J. Galloway ◽  
Brian L. Egleston ◽  
Jessica R. Bauman ◽  
Barbara Ebersole ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Supportive Care ◽  
Head And Neck ◽  
Neck Cancer ◽  
Self Efficacy ◽  
Radiation Treatment ◽  
Web Based ◽  
Coping With Cancer ◽  
Wide Range ◽  
The Web

Patients undergoing radiation treatment for head and neck cancer experience significant side-effects that can impact a wide range of daily activities. Patients often report receiving insufficient information during and after treatment, which could impede rehabilitation efforts; they may also encounter practical and logistical barriers to receipt of supportive care. Thus, we developed a web-based program, My Journey Ahead, to provide information and strategies for managing symptom-focused concerns, which may be easily accessed from the patient’s home. The purpose of this study was to evaluate patient acceptability and satisfaction with the My Journey Ahead program. In Phase 1, five patients with head and neck squamous cell carcinoma (HNSCC) reviewed the web-based program and provided initial feedback, which informed program modifications. In Phase 2, 55 patients were recruited to evaluate the program. Patient assessments were obtained prior to and after use of the web-based program, and included measures of psychological distress, self-efficacy in coping with cancer-related issues, and satisfaction with the website. Among the 55 patients enrolled, 44 logged in and viewed the web-based program. Participants reported high levels of satisfaction with the information received, and indicated that the website was interesting and easy to use. Older age and higher levels of self-efficacy in coping were each associated with higher levels of satisfaction with the website. In summary, the web-based program was well-received by patients, the majority of whom found it to be informative and useful. An easy-to-use web-based program, particularly for older patients who may have difficulty locating reliable evidence-based information on the internet, may be helpful in addressing survivors’ needs in symptom management and coping with cancer.Clinical Trial Registrationhttps://clinicaltrials.gov/, NCT02442336

Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin and Docetaxel within the CEFCID Trial

2021 ◽  
Author(s):  
Ute Goerling ◽  
Thomas Gauler ◽  
Andreas Dietz ◽  
Viktor Grünwald ◽  
Stephan Knipping ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Treatment Time ◽  
Life Questionnaire ◽  
European Organization ◽  
Global Quality Of Life ◽  
The Impact

Introduction: CeFCiD was a multicenter phase II study comparing the efficacy of cetuximab, 5-flourouracil, cisplatin with the same regimen adding docetaxel in recurrent/metastatic head and neck cancer. The primary analysis trial did not demonstrate survival benefit from therapy intensification in first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The current analysis of the trial assessed the impact of treatment on quality of life (QoL). Methods: The European Organization for Research and Treatment of Cancer Quality of life Questionnaire QLQ-C30 and the tumor specific module for head and neck cancer (QLQ-H&N35) were used to assess QoL at baseline (visit 1), after 2 (visit 3), 4 (visit 5), and 6 (visit 7) cycles of chemotherapy. Results: Of 180 patients included in this study, 86 patients (47.8%) completed the questionnaires at baseline. Considering selected scores over treatment time, there was no difference in global quality of life, dyspnea, swallowing and speech between the treatment arms in the course. For fatigue a significant increase from baseline to visit 3 (p=0.02), visit 5 (p=0.002), and to visit 7 (p=0.003) was observed for patients receiving docetaxel (D), cisplatin or carboplatin (P), 5-FU (F) and cetuximab (C). At the end of chemotherapy the manifestation of fatigue was similar compared in the two treatment arms. Discussion/Conclusion: Therapy intensification not adversely affect selected scores of QoL of patients with recurrent and/or metastatic SCCHN. Nevertheless, fatigue seems to be pronounced in patients treated with docetaxel.

Sign in / Sign up

Export Citation Format

Share Document